Open Nav

Acquist Therapeutics, Inc.

Partnering and Series A funding

  • Date:Wednesday, October 17
  • Time:11:30 AM - 11:45 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Relburn/Acquist develops small molecules that deplete uric acid (UA), an established inflammatory mediator in NASH and gout, conditions with high prevalence and grossly unmet need. Our drugs block lipogenesis and NASH progression in models with elevated UA (~40% of patients). In liver cells, we sharply reduce UA, triglycerides, lipogenesis, and inflammation. Our drugs bifunctionally inhibit regulators of both UA production and excretion (xanthine oxidase and URAT1) at potencies that exceed monofunctional drugs (e.g., allopurinol, febuxostat and lesinurad). Our clinical drug prototype (RLBN1001) reduced UA below targets in 100% of patients. Our executives have extensive experience in drug development. Global composition patents are wholly owned. Optimized for 1st-line, once-daily oral dosing, our lead (RLBN1127) is completing animal tox to confirm activity in biomarker-defined populations. We are raising a Series A and are interested in meeting qualified investors and partners.
  • Company Website:www.relburn.com
  • Company HQ City:Westfield, NJ
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • Year Founded:2013
  • Main Therapeutic Focus:Inflammation
  • Lead Product in Development :RLBN1127
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Total Amount Raised to Date, In All Rounds:$2.5M
Back